Patents Assigned to Katholieke Universiteit Leuven, K.U. Leuven R&D
  • Publication number: 20210087554
    Abstract: The present application relates to the field of inflammatory diseases, particularly to inflammatory diseases characterized by an M1 macrophage response, even more particularly to sepsis and to Trypanosoma infection. The invention provides substances modulating miR210 expression and/or activity, in particular RNA molecules inhibiting miR210 expression and/or activity and medical uses of these miR210 inhibitors. Methods are disclosed to screen for medicaments for treating sepsis.
    Type: Application
    Filed: October 3, 2017
    Publication date: March 25, 2021
    Applicants: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Massimiliano MAZZONE, Anne-Theres HENZE
  • Publication number: 20210077563
    Abstract: The present invention relates to non-naturally occurring anti-bacterial peptides. More specifically the peptides can be used to treat multi-drug resistant bacterial infections. In addition, the present invention provides methods for producing anti-bacterial peptides.
    Type: Application
    Filed: May 9, 2018
    Publication date: March 18, 2021
    Applicants: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Joost Schymkowitz, Frederic Rousseau
  • Patent number: 10881746
    Abstract: The present application relates to the field of neurological diseases, particularly to dystonia, even more particularly to primary dystonia, most particularly DYT1 primary dystonia. It is disclosed that the DYT1 dystonia causative mutation in TORSIN1A leads to hyperactivation of LIPIN. The invention provides substances modulating LIPIN function, in particular RNA molecules inhibiting LIPIN function and medical uses of these LIPIN inhibitors. Methods are disclosed to screen for medicaments that counteract the effects of TORSIN1A mutation.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: January 5, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R & D
    Inventors: Rose Goodchild, Micheline Grillet
  • Patent number: 10829528
    Abstract: The present invention relates to the field of disorders of the central nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that soluble amyloid precursor protein a (sAPP?) presents a particular binding site, which allows for binding to the GABABR1a receptor, thereby causing an agonistic effect through specific binding to Sushi domain 1 of GABABR1a. As a result, the frequencies of excitatory and inhibitory postsynaptic currents are reduced. Accordingly, the invention provides compounds able to interfere with the association of sAPP? with Sushi domain 1 of GABABR1a and as such with selective impairment of GABABR1sa beneficial in neurological and psychiatric disorders. The invention as well provides methods and (high content) screening assays for the production of said compounds.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: November 10, 2020
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Joris De Wit, Heather Rice, Bart De Strooper
  • Patent number: 10767182
    Abstract: The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: September 8, 2020
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D, Agency for Science, Technology and Research
    Inventors: Jean-Christophe Marine, Ernesto Guccione, Marco Bezzi
  • Patent number: 10695737
    Abstract: A novel miniaturized and highly automated method for the controlled printing of large arrays of nano- to femtoliter droplets is presented by actively transporting mother droplets over hydrophilic-in-hydrophobic micropatches. The proposed technology consists of single plate or double-plate devices where mother droplets can be actuated and hydrophilic-in-hydrophobic micropatches on one or both plates of the device where nano- to femtoliter droplets are printed. Due to the selective wettability of the more wettable hydrophilic micropatches in a hydrophobic matrix, large nano- to femtoliter droplet arrays are created when mother droplets are transported over these arrays. The parent droplets can be moved by different droplet actuation principles, for example, by using the principle of electrowetting-on-dielectric droplet actuation. We propose another method that uses two plates that are placed on top of each other while being separated by a spacer.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: June 30, 2020
    Assignee: Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Jeroen Lammertyn, Daan Witters
  • Patent number: 10633378
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: April 28, 2020
    Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Mohamed Koukni, Arnaud Marchand, Johan Neyts, Wim Smets
  • Patent number: 10612049
    Abstract: The present invention relates to genes conferring acetic acid tolerance in yeast. More specifically, the invention relates to the use of DOT5, preferably in combination with CUP2 and/or HAA1 to obtain acid tolerance in yeast. Even more preferably, the invention relates to specific alleles of said genes, and to yeast strains comprising said specific alleles.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: April 7, 2020
    Assignees: VIB vzw, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Johan Thevelein, Jean-Paul Meijnen, Maria Remedios Foulquié Moreno
  • Patent number: 10550123
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: February 4, 2020
    Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
  • Patent number: 10540536
    Abstract: Imaging mass spectrometry (IMS) has become a prime tool for studying the distribution of biomolecules in tissue. Although IMS data sets can become very large, computational methods have made it practically feasible to search these experiments for relevant findings. However, these methods lack access to an important source of information that many human interpretations rely upon: anatomical insight. In this work, this need is addressed by (1) integrating a curated anatomical data source with an empirically acquired IMS data source, establishing an algorithm-accessible link between them; and (2) demonstrating the potential of such an IMS-anatomical atlas link by applying it toward automated anatomical interpretation of ion distributions in tissue.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: January 21, 2020
    Assignees: Katholieke Universiteit Leuven, K.U.Leuven R&D, Vanderbilt University
    Inventors: Richard M. Caprioli, Bart De Moor, Raf Van De Plas, Nico Verbeeck, Etienne Waelkens
  • Publication number: 20190337954
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Application
    Filed: July 18, 2019
    Publication date: November 7, 2019
    Applicant: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
  • Patent number: 10450320
    Abstract: A series of 1,2,6,7,9,9a-hexahydropyrazino[1,2-d][1,2,4]triazin-4-one derivatives, substituted in the 8-position by an optionally substituted fused bicyclic heteroaromatic group, and in the 3-position by a range of functional groups, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: October 22, 2019
    Assignees: UCB Biopharma SPRL, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Helen Tracey Horsley, Richard John Mears, Judi Charlotte Neuss, James Thomas Reuberson
  • Publication number: 20190316111
    Abstract: The present invention relates to novel nucleic acid sequences encoding bacterial xylose isomerases that upon transformation of a eukaryotic microbial host cell, such as yeast, to confer to the host cell the ability of isomerising xylose to xylulose. The nucleic acid sequences encode xylose isomerases that originate from bacteria such as Eubacterium sp., Clostridium cellulosi and others. The invention further relates to fermentation processes wherein the transformed host cells ferment a xylose-containing medium to produce ethanol or other fermentation products.
    Type: Application
    Filed: December 21, 2017
    Publication date: October 17, 2019
    Applicants: VIB vzw, Katholieke Universiteit Leuven, K.U. Leuven R&D, GlobalYeast N.V.
    Inventors: Johan Thevelein, Mekonnen Demeke, Maria Remedios Foulquié Moreno, Stijn De Graeve, Edgard Valdomiro Charles Belo
  • Patent number: 10377834
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: August 13, 2019
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN. K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • Publication number: 20190225662
    Abstract: The present invention relates to the field of disorders of the central nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that soluble amyloid precursor protein ? (sAPP?) presents a particular binding site, which allows for binding to the GABABR1a receptor, thereby causing an agonistic effect through specific binding to Sushi domain 1 of GABABR1a. As a result, the frequencies of excitatory and inhibitory postsynaptic currents are reduced. Accordingly, the invention provides compounds able to interfere with the association of sAPP? with Sushi domain 1 of GABABR1a and as such with selective impairment of GABABR1a beneficial in neurological and psychiatric disorders. The invention as well provides methods and (high content) screening assays for the production of said compounds.
    Type: Application
    Filed: July 14, 2017
    Publication date: July 25, 2019
    Applicants: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Joris DE WIT, Heather RICE, Bart DE STROOPER
  • Publication number: 20190209663
    Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
    Type: Application
    Filed: October 24, 2018
    Publication date: July 11, 2019
    Applicants: LYSANDO AG, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
  • Publication number: 20190190104
    Abstract: Ionic compounds containing an anion, and a cation having the following structural formula (1): R1R2R3N+-(linker1)-O-(linker2)-(FC)??(1) wherein: R1 and R2 either linear or branched alkyl groups or together form a N-heterocylic ring with the nitrogen atom to which they are joined; R3 is linear or branched alkyl group; linker1 and linker2 are alkylene chains or polyether chains; and the group FC is a fluorinated alkyl group, as well as an electrolyte material comprising such an ionic compound and a metal salt, and metal-air batteries using such an electrolyte material. The invention also relates to a metal-air battery containing an electrolyte material, wherein the electrolyte material comprises at least one ionic compound and a metal salt, and wherein at least one ionic compound contains an anion CnF2n+1COO? or CnF2n+1SO3?, where in each case n is at least 1 and at most 10.
    Type: Application
    Filed: August 16, 2016
    Publication date: June 20, 2019
    Applicants: TOYOTA MOTOR EUROPE, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Fanny BARDE, Gijs VANHOUTTE, Sandra Dorota HOJNIAK-THYSSEN, Koen BINNEMANS, Jan FRANSAER
  • Patent number: 10274452
    Abstract: The present invention relates to a method for fabricating a semiconductor device for stimulation and/or data recording of biological material to a such semiconductor device. The method comprises providing a semiconductor substrate comprising a first insulating layer; providing a patterned conductive layer on top of the first insulating layer; depositing and patterning a second insulating layer atop the patterned conductive layer; growing carbon nano-sheets atop the second insulating layer; and defining carbon nano-sheet electrode areas on the second insulating layer by etching away the carbon nano-sheets outside of the carbon nano-sheet electrode areas.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: April 30, 2019
    Assignees: IMEC, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Nadine Collaert, Daire J. Cott, Michael De Volder
  • Patent number: 10137175
    Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: November 27, 2018
    Assignees: LYSANDO AG, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
  • Patent number: D856897
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: August 20, 2019
    Assignee: Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Bart Theys, Stijn Debecker, Joris De Schutter